A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
; : 553-560, 2016.
Article
Dans En
| WPRIM
| ID: wpr-72541
Responsable en Bibliothèque :
WPRO
ABSTRACT
PURPOSE:
While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. MATERIALS ANDMETHODS:
Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively.RESULTS:
A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the malefemale ratio was 118 (70.2%)50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025).CONCLUSION:
While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Tumeurs de l'estomac
/
Adénocarcinome
/
Ethnies
/
Études rétrospectives
/
Carcinome à cellules en bague à chaton
/
Récepteur ErbB-2
/
Survie sans rechute
/
Asiatiques
/
Traitement médicamenteux
Type d'étude:
Observational_studies
/
Prognostic_studies
Limites du sujet:
Humans
langue:
En
Texte intégral:
Cancer Research and Treatment
Année:
2016
Type:
Article